#161951

VCaP 2 [DCC C] CRPC Cell line

Cat. #161951

VCaP 2 [DCC C] CRPC Cell line

Cat. #: 161951

Organism: Human

Tissue: Prostate

Disease: Cancer

Model: Tumour Cell Line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Wytske van Weerden

Institute: Erasmus University Medical Centre

Primary Citation: Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769712

Tool Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: VCaP 2 [DCC C] CRPC Cell line
  • Parental cell: VCaP
  • Organism: Human
  • Tissue: Prostate
  • Disease: Cancer
  • Model: Tumour Cell Line
  • Model description: CRPC model
  • Receptors of note: Androgen receptor
  • Description: CRPC VCaP cell lines (15 sublines made resistant to common antiandrogens through long-term passaging) - Dextran-coated charcoal-stripped FCS (DCC C). The VCaP DCC cell line was generated by long-term culturing of VCaP cells in androgen depleted medium containing dextran-coated charcoal-stripped foetal calf serum (DCC-FCS). This cell line is subclone C. These cell lines can be used to study the role of AR signalling and mechanisms of resistance to androgen deprivation therapy in CRPC.
  • Application: Tumour Modelling

Applications

  • Application: Tumour Modelling

Handling

  • Growth medium: RPMI1640 + 10% DCC-FCS
  • Storage conditions: liquid N2
  • Cultured in antibiotics: 1% Penicillin/Streptomycin

References

  • Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769714